POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).

How it works

Potassium chloride dissociates to potassium ions, which are essential for maintaining intracellular osmolarity, transmembrane electrochemical gradients, and normal neuromuscular excitability. Dextrose 5% provides a source of calories and may help shift potassium intracellularly via insulin secretion.

What the body does with it

Metabolism	Potassium is primarily excreted unchanged by the kidneys (90%) with minor fecal loss; dextrose is metabolized via glycolysis and oxidation to carbon dioxide and water.
Excretion	Renal: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion; fecal and sweat losses account for <10%.
Half-life	Not applicable; potassium is not eliminated by first-order kinetics; distribution half-life is approximately 1 hour, with terminal elimination dependent on renal function.
Protein binding	Minimal; potassium is not significantly protein-bound (<1%).
Volume of Distribution	Approximately 0.15–0.3 L/kg for total body potassium; extracellular volume is about 0.05 L/kg.
Bioavailability	IV: 100%; oral: ~90% (not applicable for this parenteral formulation).
Onset of Action	IV: Immediate upon infusion; correction of hypokalemia begins within minutes, with full electrolyte equilibration occurring within several hours.
Duration of Action	Duration is variable depending on dose and renal function; potassium levels may remain elevated for 2–6 hours post-infusion, with sustained effects as long as infusion continues.

Classification & Brands

Dosing & administration

40 mEq intravenously over 2-4 hours, not to exceed 10 mEq/hour or 200 mEq/day; requires continuous ECG monitoring.

Dosage form	INJECTABLE
Renal impairment	GFR 30-50 mL/min: reduce dose by 25%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: avoid use or reduce by 75% with monitoring.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: avoid use or reduce by 50% with monitoring.
Pediatric use	0.5-1 mEq/kg/dose intravenously over 2-4 hours, not to exceed 1 mEq/kg/hr or 40 mEq/dose; requires ECG monitoring.
Geriatric use	Initiate at lower end of dosing range (e.g., 20 mEq over 4 hours); monitor renal function and serum potassium levels more frequently; avoid in patients with decreased renal function or drugs that increase potassium.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).

Breastfeeding

Potassium is a normal component of breast milk; supplemental potassium distributes into milk, but no adverse effects in nursing infants are anticipated. The milk-to-plasma (M/P) ratio is approximately 0.1-0.2. Concomitant dextrose does not alter this profile. Breastfeeding is considered safe with therapeutic maternal use.

Teratogenic Risk

Potassium chloride is a normal physiological constituent; no teratogenic effects are expected at therapeutic doses. However, maternal hyperkalemia may cause fetal arrhythmias or acidosis. First trimester: No known structural teratogenicity. Second/Third trimester: Fetal risk is secondary to maternal electrolyte imbalance; maternal hyperkalemia >5.5 mEq/L may impair placental perfusion and cause fetal bradycardia.

Warnings & precautions

■ FDA Black Box Warning

Concentrated potassium chloride (e.g., >40 mEq per dose) must be diluted and administered via an infusion pump. Undiluted or rapid infusion can cause fatal cardiac arrhythmias.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal failure with oliguria or anuria","Addison's disease","Acute dehydration","Crush injury or extensive tissue necrosis","Patients on potassium-sparing diuretics or aldosterone antagonists unless specifically indicated"]

Clinical Precautions

Precautions

["Hyperkalemia risk, especially in patients with renal impairment, adrenal insufficiency, or concurrent use of potassium-sparing diuretics or ACE inhibitors","Use caution with metabolic acidosis and chronic renal disease","Monitor serum potassium, ECG, and clinical status during infusion","Extravasation risk; avoid undiluted infusion"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Potassium is primarily excreted unchanged by the kidneys (90%) with minor fecal loss; dextrose is metabolized via glycolysis and oxidation to carbon dioxide and water.
Excretion	Renal: >90% of potassium is excreted by the kidneys, primarily via distal tubular secretion; fecal and sweat losses account for <10%.
Half-life	Not applicable; potassium is not eliminated by first-order kinetics; distribution half-life is approximately 1 hour, with terminal elimination dependent on renal function.
Protein binding	Minimal; potassium is not significantly protein-bound (<1%).
Volume of Distribution	Approximately 0.15–0.3 L/kg for total body potassium; extracellular volume is about 0.05 L/kg.
Bioavailability	IV: 100%; oral: ~90% (not applicable for this parenteral formulation).
Onset of Action	IV: Immediate upon infusion; correction of hypokalemia begins within minutes, with full electrolyte equilibration occurring within several hours.
Duration of Action	Duration is variable depending on dose and renal function; potassium levels may remain elevated for 2–6 hours post-infusion, with sustained effects as long as infusion continues.

Classification & Brands

Dosing & administration

40 mEq intravenously over 2-4 hours, not to exceed 10 mEq/hour or 200 mEq/day; requires continuous ECG monitoring.

Dosage form	INJECTABLE
Renal impairment	GFR 30-50 mL/min: reduce dose by 25%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: avoid use or reduce by 75% with monitoring.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: avoid use or reduce by 50% with monitoring.
Pediatric use	0.5-1 mEq/kg/dose intravenously over 2-4 hours, not to exceed 1 mEq/kg/hr or 40 mEq/dose; requires ECG monitoring.
Geriatric use	Initiate at lower end of dosing range (e.g., 20 mEq over 4 hours); monitor renal function and serum potassium levels more frequently; avoid in patients with decreased renal function or drugs that increase potassium.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER (POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

Concentrated potassium chloride (e.g., >40 mEq per dose) must be diluted and administered via an infusion pump. Undiluted or rapid infusion can cause fatal cardiac arrhythmias.